Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of heterologous SYS6006 mRNA COVID-19 booster versus recombinant protein vaccine
ChiCTR2200066941Phase 3Recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SYS6006 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The First Hospital of Hebei Medical University. Primary endpoints: Solicited local and systemic adverse events, Unsolicited adverse events and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
SYS6006
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200066941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066941.